Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04203056 · ClinicalTrials.gov registry record · Phase 4
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
A Phase 4 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT04203056: Clinical Trial Phase 4 study, sponsored by University of California, Los Angeles.
NCT04203056 is a Phase 4 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04203056, a Phase 4 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
Primary Outcome
Number of participants who experienced an exacerbation and/or relapse following a period of absence or relative low levels of psychotic symptoms based on the expanded 24-item version of the Brief Psychiatric Rating Scale
Interventions
- DRUG Aripiprazole Lauroxil
- DRUG ARI-ORAL
- DRUG AL-NCD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 4 |
Why NCT04203056 stopped before completion
NCT04203056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Aripiprazole Lauroxil is the first listed.
NCT04203056 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04203056 about?
NCT04203056 is a clinical study titled "Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode". This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
What is the current status of trial NCT04203056?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2019-12-16. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT04203056?
The interventions under investigation include: Aripiprazole Lauroxil (DRUG), ARI-ORAL (DRUG), AL-NCD (DRUG).
Who is sponsoring clinical trial NCT04203056?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04203056's enrollment target sits among peer trials
15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI